Draft Label Comprehension Study Guidance Stresses Quality And Quantity
This article was originally published in The Tan Sheet
Executive Summary
FDA wants sponsors conducting label comprehension studies to take into account subjects' thought processes - reflected in their verbatim answers to test questions
You may also be interested in...
Label Comprehension Guidance May Improve Switch Outlook
Final guidance for label comprehension studies replaces several draconian draft recommendations with more flexible "common sense" measures, but drug sponsors may need to conduct significantly larger, more expensive studies and meet more extensively with the agency, experts say
No Simple Answers To Simplifying OTC Labels – NDAC Panel
Members of FDA's Nonprescription Drug Advisory Committee said making labels effective for low literacy consumers depends as much on deciding what information to include as on the language used
NDAC Calls For Predefined Endpoints In Consumer Behavior Trials
Rx-to-OTC switch sponsors will be expected to work with FDA to establish predefined endpoints for each consumer behavior trial they plan, if the agency follows advice given by the Nonprescription Drugs Advisory Committee during a Sept. 25 meeting